.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
UBS
Novartis
Chubb
Argus Health
Deloitte
Farmers Insurance
Accenture
Cantor Fitzgerald
Express Scripts

Generated: September 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Boronate ester compounds and pharmaceutical compositions thereof
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Elliott; Eric L. (Brighton, MA), Ferdous; Abu J. (Winchester, MA), Kaufman; Michael J. (Lexington, MA), Komar; Sonja A. (Belmont, MA), Mazaik; Debra L. (Holliston, MA), McCubbin; Quentin J. (Belmont, MA), Nguyen; Phuong M. (Cambridge, MA), Palaniappan; Vaithianathan (Andover, MA), Skwierczynski; Raymond D. (Andover, MA), Truong; Nobel T. (Milford, MA), Varga; Csanad M. (Newton, MA), Zawaneh; Peter N. (Cambridge, MA)
Assignee:
Application Number:14/449,275
Patent Claims: 1. A method for treating cancer, the method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (II): ##STR00018## or a pharmaceutically acceptable salt thereof, wherein: A is 0; P is R.sup.c--C(O)--; R.sup.c is R.sup.D; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; R.sup.a1 is hydrogen; each R.sup.b1 and R.sup.b2 independently is hydrogen; each R.sup.b3 and R.sup.b4 independently is --(CH.sub.2).sub.p--CO.sub.2H; wherein one of carboxylic acids optionally forms a further bond with the boron atom; p is 0 or 1; n is 0 or 1; and the cancer is multiple myeloma, recurrence of multiple myeloma, lymphoma, or recurrence of lymphoma.

2. The method of claim 1, wherein the compound of formula (II) is characterized by formula (III): ##STR00019## or a pharmaceutically acceptab1e salt thereof, wherein: A is 0; P is R.sup.c--C(O)--; R.sup.c is --R.sup.D; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; and R.sup.a1 is hydrogen.

3. The method of claim 1, wherein the compound of formula (II) is characterized by formula (IV): ##STR00020## or a pharmaceutically acceptab1e salt thereof, wherein: A is 0; P is R.sup.c--C(O)--; R.sup.c is --R.sup.D; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; and R.sup.a1 is hydrogen.

4. The method of claim 1, wherein the compound of formula (II) is characterized by formula (IIIa): ##STR00021## or a pharmaceutically acceptab1e salt thereof, wherein: A is 0; P is R.sup.c--C(O)--; R.sup.c is --R.sup.D; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; and R.sup.a1 is hydrogen.

5. The method of claim 1, wherein the compound of formula (II) is characterized by formula (IVa): ##STR00022## or a pharmaceutically acceptab1e salt thereof, wherein: A is 0; P is R.sup.c--C(O)--; R.sup.c is --R.sup.D; R.sup.D is 2,5-dichlorophenyl; R.sup.a is isobutyl; and R.sup.a1 is hydrogen.

6. The method of claim 1, wherein the patient in need of the treatment is a patient having or at risk of developing or experiencing a recurrence in a cancer selected from multiple myeloma and lymphoma.

7. The method according to any one of claims 1-6, wherein the compound of formula (II) is administered with another therapeutic agent.

8. The method of claim 7, wherein the other therapeutic agent is melphalan.

9. The method of claim 7, wherein the other therapeutic agent is lenalidomide.

10. The method of claim 1, wherein the compound or pharmaceutical composition is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.

11. The method of claim 10, wherein the compound is administered orally.

12. The method of claim 10, wherein the compound is administered intravenously.

13. The method of claim 10, wherein the compound is administered systemically or locally.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Merck
Cipla
Healthtrust
US Army
Farmers Insurance
Medtronic
Mallinckrodt
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot